Vitamin B12

Pharmacology & Research

Vitamin B12 (cobalamin) is a water-soluble, cobalt-containing B vitamin that acts as an obligatory cofactor for two enzymes — methionine synthase and methylmalonyl-CoA mutase — and its clinical story is overwhelmingly a story of deficiency correction, not of extra benefit layered on top of an adequate diet. Where a person is genuinely low (vegans, older adults with atrophic gastritis, people on metformin or with pernicious anaemia), repletion is one of the more reliably effective interventions in nutrition, and — importantly — high-dose oral B12 works about as well as injections for most people ^{1,2Reference 1Wang et al. · 2018Systematic reviewOral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency — [Cochrane systematic review]View study →Reference 2Lederle · 1998ReviewOral cobalamin for pernicious anemia: back from the verge of extinction — [clinical review]View study →}. Where a person is already replete, the evidence for the popular uses — energy, mood, general cognition — is thin to null ^{11Reference 11Markun et al. · 2021Meta-analysisEffects of vitamin B12 supplementation on cognitive function, depressive symptoms and fatigue: systematic review, meta-analysis and meta-regression — [meta-analysis]View study →}. Form matters less than marketing suggests: cyanocobalamin, methylcobalamin, hydroxocobalamin and adenosylcobalamin are largely interchangeable vitamers once absorbed, and fractional absorption is capped by intrinsic factor (~1.5–2 mcg per dose), which is precisely why corrective regimens use hundreds to thousands of micrograms.

1. Correcting deficiency & pernicious anaemia

This is B12’s core, best-evidenced use. A Cochrane review of RCTs found that oral B12 (1,000–2,000 mcg/day) normalises serum B12 as well as intramuscular injection, at lower cost — overturning the long-held belief that deficiency must be treated by injection ^{1Reference 1Wang et al. · 2018Systematic reviewOral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency — [Cochrane systematic review]View study →}. High-dose oral therapy works even in pernicious anaemia (where intrinsic factor is absent) because ~1% of a large dose is absorbed by passive diffusion, independent of intrinsic factor — a fact clinicians were historically slow to adopt ^{2Reference 2Lederle · 1998ReviewOral cobalamin for pernicious anemia: back from the verge of extinction — [clinical review]View study →}. Even physiological oral doses (2 mcg/day) corrected anaemia, lowered homocysteine and improved nerve conduction in deficient adolescents over 11 months ^{3Reference 3Yajnik et al. · 2019A physiological dose of oral vitamin B-12 improves haematological, biochemical and nerve-function indices — [intervention trial]View study →}. Form (cyano- vs methylcobalamin) does not change this outcome.

Gap: Trials are small and short (3–4 months); they confirm biochemical and haematological correction, but few report patient-centred symptom or quality-of-life outcomes head-to-head ^{1Reference 1Wang et al. · 2018Systematic reviewOral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency — [Cochrane systematic review]View study →}.

2. Deficiency-related neuropathy

In a 1-year, double-blind, placebo-controlled RCT of 90 type-2 diabetics with B12 <400 pmol/L on long-term metformin, oral methylcobalamin 1,000 mcg/day significantly improved sural nerve conduction velocity and action potential, vibration threshold, pain score and quality of life, while the placebo group deteriorated ^{4Reference 4Didangelos et al. · 2021RCTVitamin B12 supplementation in diabetic neuropathy: a 1-year, randomized, double-blind, placebo-controlled trial — [RCT]View study →}. A systematic review of 15 RCTs (1,707 patients) found mecobalamin in combination improved clinical efficacy and nerve-conduction outcomes (RR 1.32, 95% CI 1.21–1.45), though mecobalamin alone was less clearly effective and most trials were high risk of bias ^{5Reference 5Sawangjit et al. · 2020Meta-analysisEfficacy and safety of mecobalamin on peripheral neuropathy: systematic review and meta-analysis of RCTs — [meta-analysis]View study →}. A 2026 RCT found 1,000 mcg and 2,000 mcg oral doses improved neuropathic symptoms similarly in B12-low diabetics — no benefit from the higher dose ^{6Reference 6Mansour et al. · 2026RCTOral vitamin B-12 1000 μg vs 2000 μg on neuropathic outcomes in diabetic peripheral neuropathy — [RCT]View study →}.

Gap: The convincing signal is confined to people who are B12-deficient to begin with; there is no good evidence that B12 helps neuropathy in replete patients, and the strongest meta-analytic effects come from combination regimens and lower-quality Asian trials ^{5Reference 5Sawangjit et al. · 2020Meta-analysisEfficacy and safety of mecobalamin on peripheral neuropathy: systematic review and meta-analysis of RCTs — [meta-analysis]View study →}.

3. Cognitive decline in high-homocysteine MCI

The VITACOG trial (266 older adults with mild cognitive impairment) gave a B-vitamin combination (folic acid 0.8 mg, B12 0.5 mg, B6 20 mg) for 2 years. It lowered homocysteine ~30%, slowed whole-brain atrophy, and — in the pre-specified subgroup with baseline homocysteine above the median — stabilised executive function, global cognition and memory ^{7,8Reference 7Smith et al. · 2010RCTHomocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment (VITACOG) — [RCT]View study →Reference 8de Jager et al. · 2012RCTCognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment — [RCT]View study →}. A follow-on imaging analysis reported up to a seven-fold reduction in atrophy of Alzheimer-vulnerable grey-matter regions, confined to the high-homocysteine participants ^{9Reference 9Douaud et al. · 2013RCTPreventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment — [RCT, imaging]View study →}. But this is one centre’s combination-therapy result, and it does not generalise: a meta-analysis of 11 trials in 22,000 people found homocysteine lowering had no effect on cognitive aging (z-score difference 0.00), and a B12-specific meta-analysis found no cognitive benefit in people without deficiency ^{10,11Reference 10Clarke et al. · 2014Meta-analysisEffects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials, 22,000 individuals — [meta-analysis]View study →Reference 11Markun et al. · 2021Meta-analysisEffects of vitamin B12 supplementation on cognitive function, depressive symptoms and fatigue: systematic review, meta-analysis and meta-regression — [meta-analysis]View study →}. A larger synthesis (95 studies) reported a small MMSE benefit from B vitamins overall but found that lower folate — not B12 or B6 — drove the association with dementia risk, reinforcing that any cognitive effect here is folate-led, not a B12 story ^{15Reference 15Wang et al. · 2022Meta-analysisB vitamins and prevention of cognitive decline and incident dementia: a systematic review and meta-analysis — [meta-analysis]View study →}.

Gap: The effect is a combination (folate-led) effect seen only in elevated-homocysteine MCI, not a general B12 cognitive benefit; the positive trial’s senior authors hold patents on B-vitamin treatment of cognitive impairment, and independent replication at scale is still lacking ^{9,10Reference 9Douaud et al. · 2013RCTPreventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment — [RCT, imaging]View study →Reference 10Clarke et al. · 2014Meta-analysisEffects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials, 22,000 individuals — [meta-analysis]View study →}.

4. Depression (adjunct, long-term)

A meta-analysis of RCTs of folate and/or B12 for depression found no reduction in depressive symptoms over days to weeks when added to antidepressants (standardised mean difference −0.12, 95% CI −0.45 to 0.22), but longer treatment (weeks to years) may reduce relapse (OR 0.33) and the onset of clinically significant symptoms in at-risk people (RR 0.65) ^{12Reference 12Almeida et al. · 2015Meta-analysisSystematic review and meta-analysis of RCTs of folate and vitamin B12 for depression — [meta-analysis]View study →}. A B12-specific meta-analysis likewise found no overall antidepressant effect in people without deficiency ^{11Reference 11Markun et al. · 2021Meta-analysisEffects of vitamin B12 supplementation on cognitive function, depressive symptoms and fatigue: systematic review, meta-analysis and meta-regression — [meta-analysis]View study →}.

Gap: Trials are few, small and heterogeneous, almost always test B12 with folate rather than alone, and the only positive signals are for long-term relapse prevention in selected populations — not acute treatment ^{11,12Reference 11Markun et al. · 2021Meta-analysisEffects of vitamin B12 supplementation on cognitive function, depressive symptoms and fatigue: systematic review, meta-analysis and meta-regression — [meta-analysis]View study →Reference 12Almeida et al. · 2015Meta-analysisSystematic review and meta-analysis of RCTs of folate and vitamin B12 for depression — [meta-analysis]View study →}.

Mechanisms

Target / pathway	Effect	Relevant to
Methionine synthase (cytosol)	Cofactor; remethylates homocysteine → methionine (with 5-MTHF folate)	Homocysteine lowering; DNA methylation; folate “trap” when B12 low
Methylmalonyl-CoA mutase (mitochondria)	Cofactor; converts methylmalonyl-CoA → succinyl-CoA	Fatty-acid/amino-acid catabolism; MMA rises when B12 low (deficiency marker)
Myelin maintenance	Downstream of the two enzyme roles	Neuropathy; subacute combined degeneration
Erythropoiesis / DNA synthesis	Thymidylate supply via folate cycle	Megaloblastic anaemia in deficiency

Pharmacokinetics

Dietary B12 is released from food protein by gastric acid/pepsin, bound to intrinsic factor (secreted by gastric parietal cells) and absorbed in the terminal ileum. This receptor-mediated route is saturable at ~1.5–2 mcg per meal, so absorption efficiency falls sharply as dose rises — a single large dose is mostly wasted through that channel. However, roughly 1% of any oral dose is absorbed by passive diffusion independent of intrinsic factor, which is why 1,000–2,000 mcg/day oral tablets can treat pernicious anaemia despite the absence of intrinsic factor ^{1,2Reference 1Wang et al. · 2018Systematic reviewOral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency — [Cochrane systematic review]View study →Reference 2Lederle · 1998ReviewOral cobalamin for pernicious anemia: back from the verge of extinction — [clinical review]View study →}. The body stores 2–5 mg (mostly hepatic), enough for several years, so deficiency develops slowly and, once corrected, is slow to recur. Excess is renally excreted, underpinning the low toxicity. Serum B12 is an imperfect marker; methylmalonic acid and homocysteine are more sensitive functional indicators of deficiency.

Clinical trials

B12 is off-patent and cheap, so most modern trial activity is combination B-vitamin work (cardiovascular, cognitive) or deficiency-repletion and neuropathy studies out of Asia and Europe rather than industry-driven programmes; registered activity continues, principally in diabetic neuropathy and cognitive aging.

Last checked: July 2026.

Dietary Sources

Vitamin B12 is synthesised only by microorganisms; it enters the human diet almost exclusively through animal foods, where it has accumulated up the food chain. Plant foods contain essentially none — so people avoiding animal products depend on fortified foods (some breakfast cereals, nutritional yeast) or supplements. Absorption from food is limited by intrinsic factor to roughly 1.5–2 mcg per meal regardless of how much the food contains, and up to 10–30% of older adults cannot liberate B12 from food protein efficiently (food-cobalamin malabsorption) even while absorbing the crystalline form in supplements and fortified foods normally.

Food (typical serving)	Approx. B12	Notes
Clams (3 oz)	~84 mcg	Richest common source
Beef liver (3 oz)	~70 mcg	Very high
Trout / salmon (3 oz)	~3–5 mcg	Also omega-3s
Tuna, beef (3 oz)	~2.5 mcg	—
Milk / yoghurt (1 cup)	~1.2–1.4 mcg	Well absorbed
Egg (1 large)	~0.5 mcg	Lower bioavailability
Fortified cereal / nutritional yeast	~0.6–6 mcg	The reliable plant-based route (crystalline B12)

Amounts per the NIH Office of Dietary Supplements Vitamin B12 fact sheet. The main dietary risk factor is simply avoiding animal foods without fortification.

Dosage & Intake

• RDA (adults): 2.4 mcg/day; pregnancy 2.6 mcg; lactation 2.8 mcg (IOM Dietary Reference Intakes).
• Upper limit: None established. B12 has very low toxicity and no UL — but “no UL” reflects lack of observed harm, not evidence that any dose is beneficial.
• Correcting deficiency: oral 1,000–2,000 mcg/day normalises status as effectively as intramuscular injection for most people, including many with pernicious anaemia, because ~1% is absorbed passively ^{1,2Reference 1Wang et al. · 2018Systematic reviewOral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency — [Cochrane systematic review]View study →Reference 2Lederle · 1998ReviewOral cobalamin for pernicious anemia: back from the verge of extinction — [clinical review]View study →}. Injections (hydroxocobalamin, 1,000 mcg) remain standard where malabsorption is severe or neurological signs are present.
• Form: cyanocobalamin (most stable/cheapest), methylcobalamin, hydroxocobalamin and adenosylcobalamin are effectively interchangeable vitamers once absorbed — the body interconverts them. No convincing trial shows a clinically meaningful advantage of “active” methylcobalamin over cyanocobalamin for correcting deficiency, though cyanocobalamin is theoretically avoided in rare hereditary optic neuropathy and severe renal impairment.
• Because it is not a weight-based mineral, “elemental” adjustments do not apply — B12 is dosed directly in micrograms.

These are doses studied in research, not a personal recommendation.

Safety

Vitamin B12 is among the safest vitamins: the body excretes what it cannot store, and no Tolerable Upper Intake Level has been established, so corrective doses of hundreds to a thousand-plus micrograms are used freely ^{1Reference 1Wang et al. · 2018Systematic reviewOral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency — [Cochrane systematic review]View study →}. Reported adverse effects are uncommon and mild — occasional acneiform or rosacea-like skin eruptions with high-dose supplementation. A more important clinical caveat is interpretive: an elevated serum B12 in someone not supplementing can be a marker of underlying liver or haematological disease and warrants investigation rather than reassurance.

Interactions (drug classes checked): Metformin lowers B12 absorption with long-term use (screen/supplement diabetics). Proton-pump inhibitors and H2 blockers reduce acid-dependent release of food B12 over years. Nitrous oxide irreversibly inactivates B12 and can precipitate acute deficiency in those with marginal stores. High-dose folic acid can mask the anaemia of B12 deficiency while neurological damage progresses — a longstanding reason to check B12 before treating with folate.

Who should be cautious: people relying on injections due to malabsorption should not switch to oral without monitoring if neurological signs are present; those with hereditary Leber optic neuropathy should avoid cyanocobalamin.

Pregnancy & lactation

Verdict: recommended at RDA levels; supplementation is important for those at risk. B12 needs rise modestly in pregnancy (2.6 mcg) and lactation (2.8 mcg), and maternal deficiency — particularly in vegan or vegetarian mothers — can cause serious neurological harm in exclusively breastfed infants. Routine supplemental doses are considered safe; there is no evidence of harm from typical prenatal amounts.

Scope of this safety review (for honesty, not a claim):

• Interactions assessed? Yes — metformin, acid-suppressing drugs (PPIs/H2 blockers), nitrous oxide, and folic-acid masking were reviewed.
• Pregnancy/lactation assessed? Yes — increased need in pregnancy/lactation and infant risk from maternal deficiency.
• Upper Limit? No UL set by the IOM. This reflects low observed toxicity, not evidence that megadoses are beneficial — do not infer that unlimited intake is useful or risk-free.

References